ArticleEuropean journal of nutrition2025
Higher diet quality is associated with a lower prevalence of MASLD and adverse health outcomes: insights from NHANES 2005 to 2020.
Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Association of Life's Essential 8 with Hepatic Fibrosis, MASLD, and MetALD in the Framingham Heart Study.Nutrients · 2026Article
- Article
- Association between cumulative changes of the C-reactive protein-triglyceride glucose index and the incidence of rapid kidney function decline: a nationwide prospective cohort study.Frontiers in nutrition · 2026Article
- Association between triglyceride-glucose index-a body shape index and atherosclerotic cardiovascular disease, and the modification effect of dietary patterns.Frontiers in nutrition · 2026Article
- The association between red blood cell distribution width-to-albumin ratio andFrontiers in nutrition · 2026Article
- Soft drink consumption and liver fibrosis in type 2 diabetes.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMASLD affects over 30% of the global population increasing the risk of adverse health outcomes. Improvements in diet quality (DQ) may offer a modifiable solution. This study explored the association between DQ and MASLD prevalence, advanced fibrosis, and all-cause mortality.
methodsParticipants from the NHANES U.S. national database were included in the cross-sectional (n = 20,502) and longitudinal (n = 13,161) analysis. DQ assessed using Healthy Eating Index (HEI)-2020, Mediterranean Diet Score (MedDietScore), and Dietary Approach to Stop Hypertension (DASH). MASLD and advanced fibrosis identified by the Fatty Liver Index and NAFLD fibrosis score, respectively. Mortality was ascertained by the National Death Index. Multivariate logistic regression and Cox proportional hazards analysis estimated odds ratios (OR) for MASLD and hazard ratios (HR) for mortality, with 95% confidence interval.
resultsEach 1-SD increase (improvement) in HEI-2020 and MedDietScore was associated with 25% lower likelihood of MASLD, while DASH showed 31% lower likelihood. Each 1‑SD increase in HEI‑2020, MedDietScore, and DASH was associated with lower ORs for advanced fibrosis in the MASLD group: 0.83 (0.74-0.94), 0.84 (0.75-0.95), and 0.78 (0.68-0.89), respectively. Over 9.3 years' median follow‑up, higher DQ was associated with lower all‑cause mortality in the overall population [HEI‑2020: 0.93 (0.86-0.99); MedDietScore: 0.92 (0.86-0.99); DASH: 0.89 (0.83-0.96)], with similar trends in the non‑MASLD group but not in those with MASLD or advanced fibrosis.
conclusionsHigher DQ was associated with lower likelihood of MASLD and advanced fibrosis in U.S. adults and was protective against all-cause mortality in overall and non-MASLD population but not in those with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.